Paper12552003
Developing novel oncolytic adenoviruses through bioselection.
Yan W and 12 others. J Virol, 2003. Cited by 41 papers, by iCite.
Cite this record
ConductScience Library. Developing novel oncolytic adenoviruses through bioselection. Papers, record 12552003. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/12552003
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenoviruses, Human | Major topic |
| Selection, Genetic | Major topic |
| Cytopathogenic Effect, Viral | |
| Humans | |
| Mutagenesis | |
| Serial Passage | |
| Tumor Cells, Cultured | |
| Virology | |
| Virus Replication |
Source PubMed
References51
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 6823011 | Sequence arrangement and protein coding capacity of the adenovirus type 2 "i" leader. | J Virol | 1983 | https://conductscience.org/library/papers/6823011 | PubMed |
| 2 | 10888838 | Replicative adenoviruses for cancer therapy. | Nat Biotechnol | 2000 | https://conductscience.org/library/papers/10888838 | PubMed |
| 3 | 11433341 | Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. | Nat Med | 2001 | https://conductscience.org/library/papers/11433341 | PubMed |
| 4 | 12086848 | Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. | Cancer Cell | 2002 | https://conductscience.org/library/papers/12086848 | PubMed |
| 5 | 10837552 | Conditionally replicative adenoviruses for cancer therapy. | Adv Drug Deliv Rev | 1997 | https://conductscience.org/library/papers/10837552 | PubMed |
| 6 | 11313807 | Expansion of tropism of a feline parvovirus to target a human tumor cell line by display of an alpha(v) integrin binding peptide on the capsid. | Gene Ther | 2001 | https://conductscience.org/library/papers/11313807 | PubMed |
| 7 | 11208818 | Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. | J Clin Oncol | 2001 | https://conductscience.org/library/papers/11208818 | PubMed |
| 8 | 11393279 | A herpes simplex virus type 1 mutant deleted for gamma34.5 and LAT kills glioma cells in vitro and is inhibited for in vivo reactivation. | Cancer Gene Ther | 2001 | https://conductscience.org/library/papers/11393279 | PubMed |
| 9 | 8828146 | Molecular evolution of aphthoviruses. | Virus Genes | 1995 | https://conductscience.org/library/papers/8828146 | PubMed |
| 10 | 10741699 | A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. | Clin Cancer Res | 2000 | https://conductscience.org/library/papers/10741699 | PubMed |
| 11 | 7585090 | Rapid genomic evolution of a non-virulent coxsackievirus B3 in selenium-deficient mice results in selection of identical virulent isolates. | Nat Med | 1995 | https://conductscience.org/library/papers/7585090 | PubMed |
| 12 | 7749317 | Viruses and apoptosis. | Curr Opin Genet Dev | 1995 | https://conductscience.org/library/papers/7749317 | PubMed |
| 13 | 14329143 | ISOLATION OF TEMPERATURE-SENSITIVE MUTANTS OF POLYOMA VIRUS. | Virology | 1965 | https://conductscience.org/library/papers/14329143 | PubMed |
| 14 | 1457005 | The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. | Proc Natl Acad Sci U S A | 1992 | https://conductscience.org/library/papers/1457005 | PubMed |
| 15 | 10644974 | A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. | Oncogene | 2000 | https://conductscience.org/library/papers/10644974 | PubMed |
| 16 | 10932190 | Molecular breeding of viruses. | Nat Genet | 2000 | https://conductscience.org/library/papers/10932190 | PubMed |
| 17 | 11313778 | Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? | Gene Ther | 2001 | https://conductscience.org/library/papers/11313778 | PubMed |
| 18 | 2459413 | Evidence for two points of restriction in the expression of adenovirus type 2 in cultured epidermal keratinocytes. | J Virol | 1988 | https://conductscience.org/library/papers/2459413 | PubMed |
| 19 | 3005630 | Biosynthesis and properties of the adenovirus 2 L1-encoded 52,000- and 55,000-Mr proteins. | J Virol | 1986 | https://conductscience.org/library/papers/3005630 | PubMed |
| 20 | 4627331 | Selection and preliminary characterization of temperature-sensitive mutants of type 5 adenovirus. | J Virol | 1972 | https://conductscience.org/library/papers/4627331 | PubMed |
Cited by26
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41716467 | Potency-enhancing mutations in E3-19K and i-leader increase the cytolytic activity of the PH20/SPAM1-armed oncolytic adenovirus Ad5Δ24RGD. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/41716467 | PubMed |
| 39772264 | Optimized Directed Virus Evolution to Accelerate the Generation of Oncolytic Coxsackievirus B3 Adapted to Resistant Colorectal Cancer Cells. | Viruses | 2024 | https://conductscience.org/library/papers/39772264 | PubMed |
| 38664647 | Fast Track Adaptation of Oncolytic Coxsackie B3 Virus to Resistant Colorectal Cancer Cells - a Method to Personalize Virotherapy. | Biol Proced Online | 2024 | https://conductscience.org/library/papers/38664647 | PubMed |
| 34373477 | A new insight into aggregation of oncolytic adenovirus Ad5-delta-24-RGD during CsCl gradient ultracentrifugation. | Sci Rep | 2021 | https://conductscience.org/library/papers/34373477 | PubMed |
| 34040797 | Experimental virus evolution in cancer cell monolayers, spheroids, and tissue explants. | Virus Evol | 2021 | https://conductscience.org/library/papers/34040797 | PubMed |
| 33167307 | Simultaneous Tumor and Stroma Targeting by Oncolytic Viruses. | Biomedicines | 2020 | https://conductscience.org/library/papers/33167307 | PubMed |
| 33103620 | A mutation in C. neoformans mitochondrial NADH dehydrogenase results in increased virulence in mice. | Virulence | 2020 | https://conductscience.org/library/papers/33103620 | PubMed |
| 32340119 | Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic Adenoviruses. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32340119 | PubMed |
| 31694943 | Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells. | J Virol | 2020 | https://conductscience.org/library/papers/31694943 | PubMed |
| 27999391 | Adenovirus with DNA Packaging Gene Mutations Increased Virus Release. | Viruses | 2016 | https://conductscience.org/library/papers/27999391 | PubMed |
| 27314377 | Development of an Oncolytic Adenovirus with Enhanced Spread Ability through Repeated UV Irradiation and Cancer Selection. | Viruses | 2016 | https://conductscience.org/library/papers/27314377 | PubMed |
| 25010337 | Experimental evolution of an oncolytic vesicular stomatitis virus with increased selectivity for p53-deficient cells. | PLoS One | 2014 | https://conductscience.org/library/papers/25010337 | PubMed |
| 24503714 | Species D human adenovirus type 9 exhibits better virus-spread ability for antitumor efficacy among alternative serotypes. | PLoS One | 2014 | https://conductscience.org/library/papers/24503714 | PubMed |
| 24434571 | The combination of i-leader truncation and gemcitabine improves oncolytic adenovirus efficacy in an immunocompetent model. | Cancer Gene Ther | 2014 | https://conductscience.org/library/papers/24434571 | PubMed |
| 22312363 | Oncolytic viruses: the power of directed evolution. | Adv Virol | 2012 | https://conductscience.org/library/papers/22312363 | PubMed |
| 22140489 | Replication and virus-induced transcriptome of HAdV-5 in normal host cells versus cancer cells--differences of relevance for adenoviral oncolysis. | PLoS One | 2011 | https://conductscience.org/library/papers/22140489 | PubMed |
| 22011643 | A cathepsin-cleavage site between the adenovirus capsid protein IX and a tumor-targeting ligand improves targeted transduction. | Gene Ther | 2012 | https://conductscience.org/library/papers/22011643 | PubMed |
| 21994711 | Increasing the efficacy of oncolytic adenovirus vectors. | Viruses | 2010 | https://conductscience.org/library/papers/21994711 | PubMed |
| 21863000 | Adenovirus i-leader truncation bioselected against cancer-associated fibroblasts to overcome tumor stromal barriers. | Mol Ther | 2012 | https://conductscience.org/library/papers/21863000 | PubMed |
| 21477385 | Truncating the i-leader open reading frame enhances release of human adenovirus type 5 in glioma cells. | Virol J | 2011 | https://conductscience.org/library/papers/21477385 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/12552003
GET https://conductscience.org/api/papers/v1/12552003/references?page=2